drugset / Trial / NCT02215252

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

NCT02215252

Phase 2 Completed 141 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)

Timeline

Start
2014-11-10
Primary completion
2015-07-15
Completion
2015-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05089771 Small molecule 150 mg Oral
Subject Pregabalin Small molecule 150 mg Oral